Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.58 |
| ▸ | TACR1 | P25103 | 2/20 | 0.57 |
| ▸ | CTSL | P07711 | 7/20 | 0.56 |
| ▸ | CTSB | P07858 | 5/20 | 0.56 |
| ▸ | CTSS | P25774 | 2/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9556498 | 1.00 | CAPN1 (0.58) | CAPN1TACR1CTSLCTSBCTSS | |
| SCHEMBL16321202 | 1.00 | CAPN1 (0.58) | CAPN1TACR1CTSLCTSBCTSS | |
| SCHEMBL16322231 | 1.00 | CAPN1 (0.58) | CAPN1TACR1CTSLCTSBCTSS | |
| SCHEMBL16322884 | 1.00 | CAPN1 (0.58) | CAPN1TACR1CTSLCTSBCTSS | |
| SCHEMBL9556974 | 0.95 | CTSB (0.57) | CAPN1TACR1CTSLCTSBCTSS | |
| SCHEMBL9556978 | 0.95 | CTSB (0.57) | CAPN1TACR1CTSLCTSBCTSS | |
| SCHEMBL16323443 | 0.90 | CTSL (0.57) | CAPN1TACR1CTSLCTSBCTSS | |
| SCHEMBL16322478 | 0.90 | CTSL (0.57) | CAPN1TACR1CTSLCTSBCTSS | |
| SCHEMBL1037693 | 0.90 | CTSL (0.57) | CAPN1TACR1CTSLCTSBCTSS | |
| SCHEMBL16323306 | 0.90 | CTSL (0.57) | CAPN1TACR1CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10702571-B2 | Materials for cathepsin B enhancement and methods of use | THE UNIVERSITY OF NORTH CAROLINA AT PEMBROKE (US) | 2020-07-07 | — | — | US | claimed |
| EP-3368048-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | Ultragenyx Pharmaceutical Inc. (US) | 2018-09-05 | — | — | EP | claimed |
| WO-2017096049-A1 | MATERIALS FOR CATHEPSIN B ENHANCEMENT AND METHODS OF USE | THE UNIVERSITY OF NORTH CAROLINA AT PEMBROKE (US) | 2017-06-08 | — | — | WO | claimed |
| WO-2017075540-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2017-05-04 | — | — | WO | claimed |
| US-20160136229-A1 | MATERIALS FOR POSITIVE CATHEPSIN B MODULATION AND METHODS OF USE FOR TREATING MILD COGNITIVE IMPAIRMENT (MCI), EARLY DEMENTIA, A-SYNUCLEINOPATHY, TRAUMATIC BRAIN INJURY, CARDIOMYOPATHY, EYE DISEASE AND SKIN DAMAGE | UNIVERSITY OF NORTH CAROLINA AT PEMBROKE (US) | 2016-05-19 | — | — | US | claimed |
| US-20020094958-A1 | Materials for lysosome modulation and methods of use thereof | CONNECTICUT, UNIVERSITY OF | 2002-07-18 | — | — | US | claimed |
| US-20230127775-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | ULTRAGENYX PHARMACEUTICAL INC. | 2023-04-27 | — | — | US | disclosed |
| US-20210228694-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | ULTRAGENYX PHARMACEUTICAL INC. | 2021-07-29 | — | — | US | disclosed |
| US-10702571-B2 | Materials for cathepsin B enhancement and methods of use | THE UNIVERSITY OF NORTH CAROLINA AT PEMBROKE (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190183985-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | ULTRAGENYX PHARMACEUTICAL INC. | 2019-06-20 | — | — | US | disclosed |
| US-20180264071-A1 | MATERIALS FOR CATHEPSIN B ENHANCEMENT AND METHODS OF USE | THE UNIVERSITY OF NORTH CAROLINA AT PEMBROKE | 2018-09-20 | — | — | US | disclosed |
| EP-3368048-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | Ultragenyx Pharmaceutical Inc. (US) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017096049-A1 | MATERIALS FOR CATHEPSIN B ENHANCEMENT AND METHODS OF USE | THE UNIVERSITY OF NORTH CAROLINA AT PEMBROKE (US) | 2017-06-08 | — | — | WO | disclosed |
| WO-2014204956-A1 | MATERIALS FOR POSITIVE CATHEPSIN B MODULATION AND METHODS OF USE FOR TREATING MILD COGNITIVE IMPAIRMENT (MCI), EARLY DEMENTIA, A-SYNUCLEINOPATHY, TRAUMATIC BRAIN INJURY, CARDIOMYOPATHY, EYE DISEASE AND SKIN DAMAGE | UNIVERSITY OF NORTH CAROLINA AT PEMBROKE (US) | 2014-12-24 | — | — | WO | disclosed |
| US-8163953-B2 | Compounds for lysosomal modulation and methods of use | UNIVERSITY OF CONNECTICUT (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2276726-A1 | COMPOUNDS FOR LYSOSOMAL MODULATION AND METHODS OF USE | University of Connecticut (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20090281178-A1 | Compounds for Lysosomal Modulation and Methods of Use | UNIVERSITY OF CONNECTICUT | 2009-11-12 | — | — | US | disclosed |
| WO-2009129532-A1 | COMPOUNDS FOR LYSOSOMAL MODULATION AND METHODS OF USE | UNIVERSITY OF CONNECTICUT (US) | 2009-10-22 | — | — | WO | disclosed |
| US-20020094958-A1 | Materials for lysosome modulation and methods of use thereof | CONNECTICUT, UNIVERSITY OF | 2002-07-18 | — | — | US | disclosed |
| US-5223486-A | Modified oligopeptide containing a diazomethyl ketone group or methylsulfonium group | UNIVERSITY RESEARCH CORPORATION (US) | 1993-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127775-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | GAA, LIPA, TTR | CAPN1 128/4885TACR1 3267/4885CTSL 100/4885 |
| US-20090281178-A1 | Compounds for Lysosomal Modulation and Methods of Use | GAA, GBA1, CTSA | CAPN1 568/4885TACR1 2078/4885CTSL 215/4885 |
| US-10702571-B2 | Materials for cathepsin B enhancement and methods of use | CTSB, CTSA, CTSE | CAPN1 73/4885TACR1 726/4885CTSL 16/4885 |
| US-20210228694-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | GAA, LIPA, TTR | CAPN1 128/4885TACR1 3267/4885CTSL 100/4885 |
| US-20190183985-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | GAA, LIPA, TTR | CAPN1 128/4885TACR1 3267/4885CTSL 100/4885 |
| US-20160136229-A1 | MATERIALS FOR POSITIVE CATHEPSIN B MODULATION AND METHODS OF USE FOR TREATING MILD COGNITIVE IMPAIRMENT (MCI), EARLY DEMENTIA, A-SYNUCLEINOPATHY, TRAUMATIC BRAIN INJURY, CARDIOMYOPATHY, EYE DISEASE AND SKIN DAMAGE | CTSB, CTSA, CTSG | CAPN1 159/4885TACR1 963/4885CTSL 15/4885 |
| US-20180264071-A1 | MATERIALS FOR CATHEPSIN B ENHANCEMENT AND METHODS OF USE | CTSB, CTSA, CTSE | CAPN1 73/4885TACR1 726/4885CTSL 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.